BioMAdvanced Diagnostics
Nicolas Bouler has a diverse work experience in the biotech/medtech industry, spanning over several companies and roles. Nicolas is currently serving as the Deputy General Manager and Chief Development Officer at BioMAdvanced Diagnostics, a biotech/medtech start-up based in Nantes. Nicolas'srole involves developing companion molecular diagnostic tests and biomarkers for patients receiving kidney or lung transplants and determining the best drug for patients with ulcerative colitis.
Prior to their current role, Nicolas worked as a Consultant Conception Dispositif Médical at Septodont, where they focused on harmonizing medical device design and verification. Nicolas also had a previous role as a Consultant at Septodont, where they were involved in the conception, verification, and validation of medical devices.
Nicolas has also worked at Graftys as part of the marketing and sales team, where they were responsible for defining and implementing marketing and sales strategies. Nicolas has experience in R&D, sales, and marketing, as well as in the valorization of R&D assets.
Earlier in their career, Nicolas held marketing and product management positions at Wright Medical and Zimmer Biomet. Nicolas also has experience in clinical and quality consulting through their own consultancy firm, N.B.Consulting, and served as a Production Manager at BioVac Santé Animale.
In summary, Nicolas Bouler has a strong background in the biotech/medtech industry, with experience in various areas such as R&D, marketing, sales, and consulting.
Nicolas Bouler pursued their education at Nantes Université. Nicolas completed their Maîtrise des Sciences et Technique degree in Physico-chimie des biotransformations from 1991 to 1992. Following this, they went on to pursue a Diplôme d'Etudes Approfondies (Master of Advanced Studies) in Physico-Chimie et Qualité des BioProduits from 1992 to 1993 at the same university.
This person is not in any teams
BioMAdvanced Diagnostics
BioMAdvanced Diagnostics is a MedTech start-up based in Nantes, spinoff from the CR2TI (Centre de Recherche Translationnelle en Transplantation et Immunologie, UMR 1064, INSERM – Nantes University) and from the University Hospital (CHU) of Nantes. BioMAdvanced Diagnostics brings a real disruption in the field of Biomarkers related to the Immune System based on 20 years of translational research. Its main goal is to enable a really personalized medicine which will greatly improve outcomes for the patient by providing unprecedented tools to clinicians. More specifically, great attention is being placed towards diminishing risks for patients through minimal invasive solutions which will enable very substantial cost reductions for the Health Systems. The first applications will concern the improvement of kidney or lungs transplanted patients’ follow up. The identification of biomarkers to evaluate, predict and diagnose the risk of transplant rejection will provide clinicians with ways of better anticipating and adapting their patients’ treatment. The goal being to reduce as much as possible numerous secondary effects. BioMAdvanced Diagnostics Tests will provide predictive scores and will be easily integrated into diagnostic and standard treatment protocols, easy to use by medical practitioners. BioMAdvanced Diagnostics is incubated by Atlanpole and supported by SATT Ouest Valorisation. In September 2022, the company announced a round of seed investment, raising 1,7 million euros.